VIVS — VivoSim Labs, Inc.
NASDAQ · Healthcare · Biotechnology
$0.28
+$0.00 (+0.47%)
VivoSim Labs, Inc. (VIVS) is a biotechnology company listed on NASDAQ. It is led by Keith E. Murphy, based in 11555 Sorrento Valley Road, San Diego, CA, United States, 92121, with about 14 employees. VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models; and bespoke services in the areas of investigational toxicology, mechanism of drug action elucidation, and other applications of complex human tissue models. The company also provides liver toxicology predictive screening and research services, as well as works on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at various stages of drug development; and uses its proprietary technologies to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. In addition, it offers 3D human tissue platform that develops novel human normal and disease models using high throughput systems, bioprinted, and flow/stretch capable 3D systems. The company was formerly known as Organovo Holdings, Inc. and changed its name to VivoSim Labs, Inc. in April 2025. VivoSim Labs, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Latest reported VIVS revenue for 2025-09-30 was $28.0K. Net income was -$2.5M. Revenue was down 24.3% from 2025-06-30 to 2025-09-30. VIVS currently screens at market cap $3.5M and trailing P/E 0.7.
Use this VIVS page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the VIVS quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the VIVS SEC filings page. Lician reads the product cache first so this HTML stays unique to VivoSim Labs, Inc. even when a live quote feed is slow.
About VivoSim Labs, Inc.
VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models; and bespoke services in the areas of investigational toxicology, mechanism of drug action elucidation, and other applications of complex human tissue models. The company also provides liver toxicology predictive screening and research services, as well as works on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at various stages of drug development; and uses its proprietary technologies to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. In addition, it offers 3D human tissue platform that develops novel human normal and disease models using high throughput systems, bioprinted, and flow/stretch capable 3D systems. The company was formerly known as Organovo Holdings, Inc. and changed its name to VivoSim Labs, Inc. in April 2025. VivoSim Labs, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
VIVS Key Statistics
Market Cap
$3.50M
Volume
525,087
Previous Close
$0.29
Day Range
$0.28 – $0.30
P/E Ratio
0.69
P/B Ratio
0.78
EPS
-$1.70
Revenue
$144.00K
Net Income
-$2.49M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+32.1%
Profit Margin
-1727.8%
Employees
14
VIVS Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $144.00K | $109.00K | $370.00K | $1.50M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$2.49M | -$14.67M | -$17.26M | -$11.45M |
| EPS (Diluted) | -$1.70 | -$19.25 | -$1.98 | -$1.32 |
Total Assets
$14.65M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$11.31M
Operating Cash Flow
-$9.46M
Free Cash Flow
$0.00
VivoSim Labs, Inc. Company Information
- Executive Chairman & Corporate Secretary
- Keith E. Murphy
- Headquarters
- 11555 Sorrento Valley Road, San Diego, CA, United States, 92121
- Website
- vivosim.ai
- Phone
- 858 224 1000
- IPO / Founded
- 2012-02-14
- Sector
- Healthcare
- Industry
- Biotechnology